Evidence map›Paper›PMID 39962586›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization.

Qingling He, Jianyang Hu, Fung-Yin Ngo, Huiqi Zhang, Lin He, Hao Huang, Tan Wu, Yilin Pan, Zihan Yang, Yuanyuan Jiang and 10 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Qingling He *Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Jianyang Hu *Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Fung-Yin Ngo *Department of Neuroscience, City University of Hong Kong, Kowloon Tong, Hong Kong.
Huiqi Zhang *Department of Neuroscience, City University of Hong Kong, Kowloon Tong, Hong Kong.
Lin HeDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Hao HuangDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Tan WuDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Yilin PanDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Zihan YangDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Yuanyuan JiangDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon Tong, Hong Kong.
Wah CheukDepartment of Pathology, Queen Elizabeth Hospital, Kowloon Tong, Hong Kong.
Gary M TseDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Julia Y TsangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Mengsu YangDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Liang ZhangDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Xin WangDepartment of Surgery, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Pui-Chi LoDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
C Geoffrey LauDepartment of Neuroscience, City University of Hong Kong, Kowloon Tong, Hong Kong.
Y Rebecca ChinDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong. rebecca.chin@cityu.edu.hk.ORCID http://orcid.org/0000-0001-8976-3466

Funding

City University of Hong Kong 7005517City University of Hong Kong 7005739City University of Hong Kong 7005872City University of Hong Kong 7020033City University of Hong Kong 9609316City University of Hong Kong 9610559City University of Hong Kong 9683001National Natural Science Foundation of China 81972781National Natural Science Foundation of China 82273470Research Grants Council, University Grants Committee 11102322Research Grants Council, University Grants Committee 11103719Research Grants Council, University Grants Committee 14104223Research Grants Council, University Grants Committee R1020-18
6 · The paper itself

Abstract

backgroundThe triple-negative subtype of breast cancer is particularly challenging to treat due to its aggressiveness with a high risk of brain metastasis, and the lack of effective targeted therapies. Tubulin beta 2B class IIb (TUBB2B), a β-tubulin isoform regulating axon guidance during embryonic development, was found to be overexpressed in various types of cancers including triple-negative breast cancer (TNBC). However, its functional roles in breast cancer or metastasis remain unclear.

methodsTo identify TUBB2B as a novel molecular target in TNBC, we performed bioinformatics analysis to assess the association of TUBB2B expression and survival of patients. RNAscope in situ hybridization was used to examine TUBB2B expression in clinical breast tumor samples. The effect of TUBB2B knockdown on TNBC growth and brain metastasis colonization was evaluated by in vitro and in vivo assays. Mass spectrometry (MS) and biochemical experiments were performed to explore the underlying mechanisms. Preclinical efficacy of targeting TUBB2B was determined in xenograft studies using the siRNA-gold nanoparticle (siRNA-AuNP) approach.

resultsTUBB2B, but not other β-tubulin isoforms, is frequently overexpressed in TNBC primary tumors as well as brain metastases. We also find that upregulation of TUBB2B is associated with poor prognosis in breast cancer patients. Silencing TUBB2B induces tumor cell death and inhibits the outgrowth of brain metastasis. Mechanistically, we identify eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) as a novel interacting partner of TUBB2B, revealing a previously unexplored role of TUBB2B in translational regulation. In line with its neural-related functions, TUBB2B overexpression in TNBC cells activates astrocytes, which in turn upregulate TUBB2B in tumor cells. These findings suggest a feed-forward interaction between TUBB2B in TNBC cells and astrocytes that promotes brain metastatic colonization. Furthermore, we demonstrate the potent inhibition of TNBC xenograft growth as well as brain metastatic colonization using TUBB2B siRNA-AuNP treatment, indicating potential clinical applications of targeting TUBB2B for TNBC.

conclusionsTUBB2B is a novel TNBC gene that plays a key role in promoting tumor cell survival and brain metastatic colonization, and can be targeted by siRNA-AuNPs as a treatment strategy.

Indexed as

Brain NeoplasmsTriple Negative Breast NeoplasmsTubulinAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceRNA, Small InterferingXenograft Model Antitumor AssaysRNA, Small InterferingTUBB2B protein, humanTubulinBrain metastatic colonizationProtein translationTriple-negative breast cancerTUBB2B

Identifiers

PMID39962586
PMCPMC11831766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.